(Q89348728)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28230061%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

title

Neurofibromatosis type 1 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28230061%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28230061%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

6

Kimberly J Johnson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28230061%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Rosalie E Ferner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28230061%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Robert H Listernick

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28230061%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Bruce R Korf

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28230061%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Pamela L Wolters

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28230061%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

23 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28230061%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Disease Primers

3 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28230061%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28230061%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

17004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28230061%20AND%20SRC:MED&resulttype=core&format=json

Identification of the neurofibromatosis type 1 gene product

3 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Incidence and mortality of neurofibromatosis: a total population study in Finland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Parental age and Neurofibromatosis Type 1: a report from the NF1 Patient Registry Initiative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Paternal age and sporadic neurofibromatosis 1: a case-control study and consideration of the methodologic issues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The importance of advanced parental age in the origin of neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Epidemiology of neurofibromatosis type 1 (NF1) in northern Finland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

On the natural history of von Recklinghausen neurofibromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Identification and characterization of the neurofibromatosis type 1 protein product

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Advances in the treatment of neurofibromatosis-associated tumours.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Somatic mutation analysis in NF1 café au lait spots reveals two NF1 hits in the melanocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromin as a regulator of melanocyte development and differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Double inactivation of NF1 in tibial pseudarthrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Long-term Cre-mediated retrograde tagging of neurons using a novel recombinant pseudorabies virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromin regulation of ERK signaling modulates GABA release and learning

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Social learning and amygdala disruptions in Nf1 mice are rescued by blocking p21-activated kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The development of cutaneous neurofibromas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

PTEN dosage is essential for neurofibroma development and malignant transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Mouse models of tumor development in neurofibromatosis type 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Innate neural stem cell heterogeneity determines the patterning of glioma formation in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The impact of coexisting genetic mutations on murine optic glioma biology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Optic nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

31 March 2020

Reply: To PMID 24375753.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Predictive Value of Café au Lait Macules at Initial Consultation in the Diagnosis of Neurofibromatosis Type 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The clinical and diagnostic implications of mosaicism in the neurofibromatoses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The natural history of spinal neurofibromatosis: a critical review of clinical and genetic features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Germline mutation of INI1/SMARCB1 in familial schwannomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Preimplantation diagnosis for neurofibromatosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Elevated risk for MPNST in NF1 microdeletion patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Late-onset optic pathway tumors in children with neurofibromatosis 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Renovascular disease and hypertension in children with neurofibromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Guidelines for the diagnosis and management of individuals with neurofibromatosis 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Emergence of optic pathway gliomas in children with neurofibromatosis type 1 after normal neuroimaging results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Scoliosis associated with neurofibromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Approaches to treating NF1 tibial pseudarthrosis: consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The nature and frequency of cognitive deficits in children with neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Impact of ADHD in adults with neurofibromatosis type 1: associated psychological and social problems.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Attention skills in children with neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromatosis type 1 and autism spectrum disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromatous neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Diagnosis, management, and complications of glomus tumours of the digits in neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Cervical cord compression from plexiform neurofibromas in neurofibromatosis 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Association between benign and malignant peripheral nerve sheath tumors in NF1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromatosis type 1: a multidisciplinary approach to care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromatous neuropathy in neurofibromatosis 1 (NF1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromatosis 1-associated neuropathies: a reappraisal.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Malignant peripheral nerve sheath tumours in neurofibromatosis 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

[18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Pediatric Malignant Peripheral Nerve Sheath Tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Precocious puberty in children with neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Brainstem lesions in neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Diagnosis and management of pheochromocytoma: a practical guide to clinicians

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Gastrointestinal stromal tumour.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Cutaneous xanthogranulomas, hepatosplenomegaly, anemia, and thrombocytopenia as presenting signs of juvenile myelomonocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Renal artery stenosis and aneurysms associated with neurofibromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Increased Risk of Cerebrovascular Disease Among Patients With Neurofibromatosis Type 1: Population-Based Approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromatosis 1 vasculopathy manifesting as a peripheral aneurysm in an adolescent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Moyamoya syndrome associated with neurofibromatosis Type 1: perioperative and long-term outcome after surgical revascularization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Parental reports of health-related quality of life in young children with neurofibromatosis type 1: influence of condition specific determinants.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Social-emotional functioning of children and adolescents with neurofibromatosis type 1 and plexiform neurofibromas: relationships with cognitive, disease, and environmental variables

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The need for a new medical model: a challenge for biomedicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Impact of neurofibromatosis 1 on Quality of Life: a cross-sectional study of 176 American cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Prevalence and clinical presentation of headache in a National Neurofibromatosis 1 Service and impact on quality of life.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Psychological burden in adult neurofibromatosis type 1 patients: impact of disease visibility on body image.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Achieving consensus for clinical trials: the REiNS International Collaboration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Optimizing biologically targeted clinical trials for neurofibromatosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Improving outcomes for neurofibromatosis 1-associated brain tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Health supervision for children with neurofibromatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

A prospective study of neurofibromatosis type 1 cancer incidence in the UK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Optic gliomas in children with neurofibromatosis type 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Increased risk of breast cancer in women with NF1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Neurofibromatosis type 1 and chronic neurological conditions in the United States: an administrative claims analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

The range of multiple sclerosis associated with neurofibromatosis type 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Epilepsy in individuals with neurofibromatosis type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Sleep disturbance as part of the neurofibromatosis type 1 phenotype in adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Prevalence of Sleep Disturbances in Children With Neurofibromatosis Type 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2017.4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRDP.2017.4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28230061%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference